|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteoporosis in all skeletal sites significantly related to increased risk of mortality in men and women, but the associations were stronger for BMD in the femur neck and total hip than in the lumbar spine.
|
30660675 |
2019 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
FN_BMD is an important risk factor for osteoporosis.
|
30172742 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using whole blood DNA methylation analysis, women at risk of developing osteoporosis can be identified before a diagnosis of osteoporosis is made using BMD as a screening method.
|
29924424 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, we describe a novel method to correct the crosstalk effect in pathway analysis and found five key independent pathways involved in BMD regulation, which may provide a better understanding of biological functional networks in osteoporosis.
|
29330445 |
2018 |
|
Osteoporosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The only quality improvement strategy for which meta-analysis findings demonstrated significant improvement of osteoporosis care for patient populations including individuals without prior fracture was patient self-scheduling of DXA plus education, for increasing the outcome of BMD testing (risk difference 13%, 95% CI 7%-18%).
|
29637658 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients who elected to discontinue osteoporosis treatment experienced a significant decline in the change in BMD compared to the change on teriparatide putting them at higher risk for recurrence of fragility fractures.
|
29541794 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, associations of U-PAHs with BMD and osteoporosis varied by specific U-PAHs and bone sites, as well as menopausal status and genders in U.S. adults.
|
29738949 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The lack of association between the common genetic variations of TGF-β1 and IL-6 genes, and BMD highlights the complex genetic background of osteoporosis in the north of Iran.
|
29860063 |
2018 |
|
Osteoporosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The DG presented a higher frequency of abnormal BMD (osteopenia in 45 (53%), and osteoporosis in 14 (19%)) and comorbidities than the CG (p < 0.005).
|
29632617 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this population of healthy, non-obese, men without a history of cardiovascular disease the positively association between cardiovascular parameters and BMD was mainly explained by weight, suggesting that in this population weight plays a protective role in the development of osteoporosis.
|
29806852 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In older people with osteoporosis, higher protein intake (≥ 0.8-g/kg body weight/day, i.e., above the current RDA) is associated with higher BMD, a slower rate of bone loss, and reduced risk of hip fracture, provided that dietary calcium intakes are adequate.
|
29740667 |
2018 |
|
Osteoporosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, teriparatide has been shown to be superior in its effects on BMD and vertebral fracture risk in glucocorticoid-treated individuals with osteoporosis and should be considered as an alternative first line option in high-risk patients.
|
29691807 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disease severity (GOLD 3 and 4) was significantly associated with higher risk of vitamin D deficiency (p = 0.032), lower BMD (both men and women at all sites), higher frequency of osteoporosis (in women at all sites), lower skeletal mass index, and higher rate of low lean mass (in both men and women) than healthy controls and COPD patients with milder disease (GOLD 1 and 2).
|
29564475 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We secondarily compared microRNA-21 expression between participants with normal and low bone mineral density (BMD: osteopenia and osteoporosis).
|
30232913 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that FRAX without BMD is not sensitive/specific enough to be used to identify Caucasian men 50 to 70 years old with BMD-defined osteoporosis.
|
29397409 |
2018 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among subjects with spine fracture, 26 % met BMD criteria for osteoporosis.
|
28175980 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the performance of OSTA is influenced by age, sex, ethnicity and site of BMD measurement to define osteoporosis.
|
28695762 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the majority of individuals who have low-trauma fractures do not have osteoporosis with DXA (i.e., T-score <-2.5), and some of them have no decreased BMD at all.
|
28161747 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The estimated BMD testing interval for 10 % of patients to develop osteoporosis was 9.6 years for those with normal BMD, 7.6 years for those with mild osteopenia, 4.7 years for those with moderate osteopenia, and 2.1 years for those with severe osteopenia.
|
27509834 |
2017 |
|
Osteoporosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The effects of icariin on various genes were detected by PCR and Western blot methods The correction between the expression of PPARγ and BMD was analyzed in patients with osteoporosis.
|
28122309 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of hydroxyproline, Gly-Gly and cystine, differed significantly between groups, with Gly-Gly and cystine significantly lower in the low BMD group and hydroxyproline, a reported marker of osteoporosis, significantly higher.
|
27989648 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The new diagnostic criteria continue to include a T-score by DXA of spine or hip that is less than or equal to -2.5, but alternatively also include a hip fracture with or without BMD testing or a vertebral, pelvis, proximal humerus and in some cases a distal forearm fracture in a person with low bone mass, or a FRAX score that meets or exceeds the NOF Guide osteoporosis treatment cut point.
|
28936598 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Administrative health claims data were used to determine monthly rates of BMD testing and initiation of osteoporosis medicines in the 9-months post-intervention among targeted men and women compared to older cohorts of men and women.
|
28188561 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Those who took osteoporosis medication during the observation study showed a smaller decline in BMD than those who did not.No new safety concerns were identified.
|
28144701 |
2017 |
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination or sequential therapies of boneforming agents and anti-resorptive agents, or two kinds of anti-resorptive agents, or strontium ranelate and other anti-osteoporosis agents have the advantages on BMD compared with monotherapy.
|
28521691 |
2017 |